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Introduction
Breast cancer incidence rates have gradually increased in Norway since the 1950s (1, 2), with a markedly stronger increase starting in the early 1990s. Breast cancer mortality remained stable from the 1950s until around 1995, since then there has been a clear and consistent decline (1) . Similar changes in incidence and mortality have been observed in most developed countries (3) (4) (5) (6) . However, long-term secular trends in incidence and prognosis of molecular subtypes of breast cancer are poorly documented.
The heterogeneous nature of breast cancer that is observed both clinically and histopathologically, is also apparent in gene expression patterns (7, 8) . Using immunohistochemistry (IHC) and in situ hybridization (ISH) as surrogates for gene expression analysis, archival tumour tissue can be reclassified into molecular subtypes (7) (8) (9) (10) (11) (12) . Our main aim was to study long-term trends in incidence of different molecular breast cancer subtypes in a population of Norwegian women born between 1886 and 1977. Our second aim was to study the prognosis of molecular breast cancer subtypes diagnosed among these women.
Materials and methods
This follow-up study comprises women from two population-based surveys conducted in study that also included two other counties (13) . We studied women from Nord-Trøndelag County, comprising a total of 25 727 women born between 1886 and 1928 who were followed for breast cancer occurrence from January 1 st , 1961 until December 31 st , 2008.
Follow-up was facilitated by the introduction of the unique 11-digit identity number of all
Norwegian citizens in 1961. In total, 1379 incident cases were diagnosed during follow-up, and 909 of these tumours were previously subtyped by our group (11) . Some tumours were diagnosed at other hospitals, in particular in the 1960s and 1970s, and tumour tissue from these cases was not available for this study. After diagnosis, all patients were followed until death from breast cancer or death from other causes, or until December 31 st , 2010. were diagnosed with breast cancer. Of these, 157 were already included in Cohort 1. Of the remaining tumours, 57 were unavailable for subtyping, resulting in a total of 514 tumours from Cohort 2 that were subtyped in the present study ( Figure 1 ). After diagnosis, these patients were followed until death from breast cancer or death from other causes, or until December 31 st , 2013.
In the present study, we merged data from the two cohorts ( Figure 1 ). In accordance with the requirements and conditions of the ethical approval of the study, patient identity was known to us for breast cancer cases but not for the underlying populations. Since there was some overlap in birth year between Cohort 1 and 2, we restricted Cohort 2 to women born after 1928 (n=27 222) to avoid duplicate observations in the incidence analyses. In the restricted cohort, there were 529 incident breast cancers, including 480 of the 514 cases that could be subtyped. In the analysis of incidence rates, we therefore used data from a total of 1908 incident breast cancers that occurred among 52 949 women; 1379 (909 subtyped cases)
from Cohort 1, and 529 (480 subtyped cases) from Cohort 2.
In the analyses of prognosis for different breast cancer subtypes, we included all 514 cases from Cohort 2 and the 909 cases from Cohort 1, yielding a total of 1423 subtyped cases.
Specimen characteristics
New 4-μm thick sections from representative paraffin blocks were stained with haematoxylin-erythrosine-saffron (HES), reviewed by two pathologists independently, and classified into histopathological type and grade (15, 16) . Any discrepancies were discussed, and consensus reached. Tumour size was measured on the glass slide, and correlated to information in the pathology report. In cases with multifocal tumours, the largest tumour was selected.
Tissue microarrays (TMA) were constructed using the Tissue Arrayer MiniCore 
Statistical analyses
During follow-up for breast cancer occurrence, censoring was done at time of death or emigration. Incidence rates were estimated separately for women born before 1929 and women born in 1929 or later. Age-specific rates were calculated to account for differences in age at baseline, and variations in age at diagnosis between subtypes. Estimates of incidence rates were plotted according to birth year and age for all incident cancers combined, and for each subtype separately. Poisson regression was used to compare incidence rates between women born before 1929 and women born in 1929 or later. The data allowed comparison of incidence rates in the age range 50-69 years. In the comparisons of Luminal A and Luminal B (HER2-), we had sufficient statistical power to use 5-year categories of age within that agerange, estimated as incidence rate ratios (IRRs) with 95% confidence intervals (CI). For the remaining subtypes, statistical power was limited and we used 10-year categories in the incidence comparisons.
For some cases, tumour tissue was unavailable, or the tumours could not be subtyped for other reasons. Thus, tumours from 34% of cases born before 1929, and 9% of cases born in 1929 or later could not be subtyped. Consequently, the observed subtype-specific incidence rates would underestimate the true rates, and underestimation would be greater for women born before 1929, because their tumour subtype was more likely to be unknown. To compensate for this, we performed multiple imputations to predict the molecular subtype of these tumours (24, 26) , assuming samples were missing at random (27) In analyses of prognosis, we distinguished between women diagnosed before 1995 and women diagnosed in 1995 or later, to approximate the gradual implementation of adjuvant treatment (including effective chemotherapy, anti-hormonal treatment and trastuzumab) in Norway (28) . For each subtype, we calculated cumulative incidence of death from breast cancer at 5 and 15 years after diagnosis, treating deaths from other causes as competing events. Gray's test was used to test equality between cumulative incidence curves.
We used Cox proportional hazards models to compare the rate of death within each diagnostic period according to molecular subtype, and to compare the rate of death for each subtype between diagnostic periods. In the latter analysis, estimations were made for the first 5 and 15 years after diagnosis, and for the entire follow-up period. We estimated hazard ratios (HRs) with 95% CIs from the month of diagnosis until death, with censoring at time of death from other causes, and with adjustments for age, stage and histopathological grade at diagnosis. No clear violations of proportionality were found in log-minus-log plots. Stata version 13.1 (Stata Corp., College Station, TX, USA) was used for statistical analyses.
Ethical approval
The study was approved by the Regional Committee Figure 2 ). The higher incidence was particularly evident in the age group 50-54 years (IRR 7.7, 95% CI 3.4-17.4 and IRR 5.9, 95% CI 2.4-14.5, respectively) and weaker in the 65-69 year age group (IRR 2.3, 95% CI 1.6-3.5 for Luminal A and IRR 1.2, 95% CI 0.6-2.3 for Luminal B (HER2-)). Although the incidence rates for Luminal B (HER2+) and non-luminal subtypes were also higher for women born in 1929 or later, the differences were much less pronounced and varied considerably between age groups.
After imputation for unknown subtype, the observed relative rates (IRR) for Luminal A and Luminal B (HER-) were strongly attenuated (Table 1) . Thus, the IRR for Luminal A breast cancer in the age group 50-54 years was reduced from 7.7 to 3.5 (95% CI 1.8-6.9), and for Luminal B (HER2-), there was a corresponding reduction in IRR from 5.9 to 2.5 (95% CI 1.2-5.2) after imputation. The IRRs for Luminal B (HER2+) and the non-luminal subtypes were almost fully attenuated after imputation (Table 1) .
Incidence analysis based on observed data for the four subtypes determined by ER, PR, and HER2 status showed a marked incidence increase for the ER+, PR+, HER2-subtype,
with an IRR of 6.9 (95% CI 3.8-12.6) for the age group 50-54 years. After imputation, the IRR was attenuated to 3.1 (95% CI 1.9-5.1). The results of these analyses are reported in detail in Supplementary Table 2 Prognosis according to molecular subtype and year of diagnosis Mean follow-up after diagnosis was 9.8 years for patients diagnosed before 1995, and 7.9 years for patients diagnosed in 1995 or later. Women diagnosed in 1995 or later were on average younger, and their tumours were more often Luminal A and of lower grade.
Furthermore, tumours diagnosed in 1995 or later were generally smaller compared to those diagnosed before 1995 (Table 2) . However, information on tumour size was frequently missing or insufficiently described in the pathology reports from the first diagnostic period.
In both diagnostic periods, Luminal A had the best prognosis, and HER2 type had the poorest (Table 3, Figure 3 ). Although the absolute risks of death for each subtype differed between diagnostic periods, the patterns of risk between subtypes remained roughly similar.
The cumulative risk of death from Luminal A breast cancer was 37 % (95% CI 32-44%) after 15 years of follow-up for women diagnosed before 1995 (Table 3 , Figure 3 ), and 13% (95% CI 9-17 %) in women diagnosed in 1995 or later, indicating a strong decline in case fatality from the first to the second diagnostic period. The corresponding cumulative risk of death for women diagnosed with HER2 type was 57% (95% CI 44-71%) and 42% (95% CI 28-60%).
We used Cox regression analysis to compare rates of death between subtypes in each diagnostic period, and found that among women diagnosed before 1995, the rate of death from HER2 type was more than twice as high (age-adjusted HR 2.3, 95% CI 1.5-3.5) as for
Luminal A. The corresponding HR for women diagnosed with HER2 type in 1995 or later was much higher (age-adjusted HR 5.1, 95% CI 2.8-9.3). Adjusting for histopathological grade or stage of disease at diagnosis did not substantially influence these results.
We also used Cox regression analysis to compare rates of death for each subtype between diagnostic periods (Table 3 ). Generally, rates of death were lower for women diagnosed in 1995 or later, although precision was low for the less common subtypes. Thus, for the entire follow-up period, the rate of death was 60% lower for Luminal A (age-adjusted Table 3 ). Analyses based on the four subtypes determined by ER, PR, and HER2 status showed that both before and after 1995, the ER+, PR+, HER2-subtype had the best prognosis (Supplementary Table 4 , and Supplementary type had the poorest in both diagnostic periods.
The participants came from a single county in Norway, which is predominantly rural and ethnically homogeneous, with little migration (14) . This increases the comparability over time within the study population. Incident tumours were reclassified into molecular subtypes and included in analyses of incidence and long-term prognosis, using reliable end-point data from national registries.
Molecular subtyping was performed in the same laboratory, using the same antibodies for IHC in all tumours. This ensured that the observed incidence differences were not caused The impact of risk factors seems to differ between molecular subtypes, and it is possible that the higher incidence of HER2 negative luminal tumours among women born in 1929 or later may also be explained by differences in reproductive and lifestyle factors, such as age at menarche, age at first birth, parity, age at menopause, and body mass index (39, 40, 46, 47) .
Some tumours were unavailable for subtyping (34% of cases born before 1929, and 9% of cases born in 1929 or later), mainly because patients were diagnosed at other hospitals.
We therefore used multiple imputations to compensate for the resulting underestimation of subtype-specific incidence rates. Even when all clinical information available is included in the imputation models, it is difficult to assess how well the imputed rates reflect the true rates for each subtype. This uncertainty is also reflected in the relatively wide confidence intervals for the imputed rates. Although weaker after imputation, the differences in incidence rates persisted for the HER2 negative luminal subtypes, whereas the observed differences for
Luminal B (HER+) and non-luminal subtypes disappeared after imputation for unknown subtype. Imputations had stronger effects on the subtype-specific rates for women born before 1929, due to a higher frequency of unknown subtype among these women.
Breast cancer mortality in Norway has declined since the mid-1990s, and this has been attributed to earlier detection (48, 49) , and improved treatment (50) (51) (52) . We found that the prognosis was generally better for women diagnosed with breast cancer in 1995 or later, compared to before 1995, confirming the findings of others (6, 23, 53) .
Differences in prognosis (9, 54) and treatment response (55, 56) between subtypes have been demonstrated, and in accordance with others, we found clear reductions in case fatality for HER2 negative luminal subtypes from the first to the second diagnostic period (6, 53) . We also found clear reductions in case fatality for the Basal phenotype.
The HER2 type had the worst prognosis irrespective of diagnostic period, and compared to Luminal A, the relative rate of death from HER2 type increased dramatically from the first to the second diagnostic period. This increase could probably be attributed to longer survival among Luminal A patients diagnosed in 1995 or later. Since Luminal tumours are more likely to be detected by screening (34) (35) (36) , it is plausible that the longer survival among many Luminal A cases diagnosed after 1995 may be due to earlier detection by mammography (lead-time bias). Aggressive subtypes, such as the Basal phenotype or the HER2 type, are more likely to present clinically, and lead-time bias may be a negligible issue for these subtypes (34) (35) (36) (37) .
Contrary to others (23), we could not demonstrate clear improvements in survival for the HER2 type between diagnostic periods. One possible explanation could be that targeted treatment with trastuzumab was not implemented until the last years of the observation period.
In conclusion, there has been a dramatic secular increase in the incidence rates of Abbreviations: IRR=Incidence rate ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2 a Based on 50 imputed datasets using age (5-year categories) and calendar year at diagnosis (continuous), stage (I, II, III, IV, unknown) and extent of disease (disease localized to the breast, local invasion, regional lymph nodes, distant lymph nodes or organ metastases, unknown) as reported by the Cancer Registry of Norway, year of birth (5-year categories), observation time after diagnosis (log-transformed, continuous) and survival status (alive, death from breast cancer, death from other causes). b Total breast cancer incidence from the Cancer Registry of Norway, including cases with unknown subtype.
c Too few observations. Abbreviations: IRR=Incidence rate ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2 a Based on 50 imputed datasets using age (5-year categories) and calendar year at diagnosis (continuous), stage (I, II, III, IV, unknown) and extent of extent of disease (disease localized to the breast, local invasion, regional lymph nodes, distant lymph nodes or organ metastases, unknown) as reported by the Cancer Registry of Norway, year of birth (5-year categories), observation time after diagnosis (log-transformed, continuous) and survival status (alive at end of follow-up, death from breast cancer, death from other causes). b Total breast cancer incidence from the Cancer Registry of Norway, including cases with unknown subtype. 
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